Here’s a conceptual paper title and abstract based on the invented term — treated as a novel compound, biological entity, or digital phenomenon. Title: Adobezii : A Novel Hybrid Compound with Dual Inhibitory Activity on TNF-α and IL-6 in a Murine Model of Acute Inflammation
adobezii, anti-inflammatory, dual cytokine inhibition, flavonoid derivative Alternatively, if you intended adobezii as a digital platform or AI tool, here’s a second version: adobezii
Background: Chronic inflammation underlies numerous autoimmune and metabolic disorders. There is a continued need for small molecules targeting multiple pro-inflammatory cytokines without immunosuppressive toxicity. The synthetic flavonoid derivative adobezii (IUPAC: 5,7-dihydroxy-2-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)chroman-4-one) was identified through computational screening against the TNF-α and IL-6 binding pockets. Methods: Molecular docking and MD simulations (100 ns) predicted stable binding to both targets. In vivo, acute inflammation was induced in BALB/c mice via intraplantar carrageenan injection. Adobezii (5, 10, 20 mg/kg, oral) was administered 1 h prior. Paw edema, myeloperoxidase activity, and serum cytokines were measured. Results: Adobezii dose-dependently reduced paw swelling (max 68% at 20 mg/kg, p<0.01), suppressed TNF-α and IL-6 by 74% and 69% respectively, and decreased neutrophil infiltration. No hepatotoxicity or weight loss was observed. Conclusion: Adobezii represents a promising dual cytokine inhibitor scaffold for further optimization in rheumatoid arthritis models. Here’s a conceptual paper title and abstract based